Kidney Cancer - A Phase II Study of M200

	UROLOGY MAIN SITE	GEN. ADULT UROLOGY	UROLOGIC ONCOLOGY	MALE UROLOGY	TRANSPLANT PROGRAM
	PELVIC MEDICINE, INCONTINENCE & RECONST. SURGERY		PEDIATRIC UROLOGY	MIN. INVASIVE SURGERY

Innovations & Technology

Research & Clinical
Trials

Facilities & Directions

How You Can Help

Department of
Urology Intranet

Clinical Trial Details

Trial Information

Trial:

Kidney Cancer - A Phase II Study of M200

Co-Investigator(s):	Arie Belldegrun, MD;

This trial is currently accepting new patient applications. (Apply)

Objective

A Phase II Study of M200 (anti-a 5ß1 integrin monoclonal antibody) in Patients with Metastatic Renal Cell Carcinoma

M200 is an anti-angiogenic a5ß1 integrin inhibitor for the treatment of solid tumors. M200 binds to a5ß1 integrin and blocks the binding of a5ß1 to fibronectin, thereby inhibiting a pivotal interaction required for angiogenesis. This mechanism of action is different from other angiogenesis inhibitors currently approved or in clinical trials, which primarily focus on inhibiting vascular endothelial growth factor (VEGF).

Principal investigator: Fairooz Kabbinavar - Hematology-Oncolory

Patient Eligibility

Inclusion Criteria:

Metastatic RCC with predominantly clear cell histology
Previously treated with 0 to 2 prior regimens for metastatic disease
Measurable Disease per RECIST criteria
Performance Status 0-1

Exclusion Criteria

Any of the following histologies: papillary, chromophobe, collecting duct, or unclassified.
CNS Tumor or metastasis
Within the past year: stroke, TIA, DVT , bleeding disorder, GI ulcer, a history of GI bleed requiring transfusion, hemoptysis, coagulation defects.
Diabetes requiring insulin, uncontrolled hypertension
Unstable cardiac disease
Coumadin (high-dose) therapy

For More Information

For additional information on inclusion and exclusion criteria and whether or not you may be a candidate to participate in a trial, call Nazy Zomorodian, Director for the Clinical Trials Office at (310) 794-7704.